Free Trial

This company has been marked as potentially delisted and may not be actively trading.

NASDAQ:APTO

Aptose Biosciences (APTO) Stock Price, News & Analysis

Aptose Biosciences logo

About Aptose Biosciences Stock (NASDAQ:APTO)

Advanced Chart

Key Stats

Today's Range
N/A
50-Day Range
$1.71
$6.86
52-Week Range
N/A
Volume
650,294 shs
Average Volume
227,964 shs
Market Capitalization
$3.66 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$6.00
Consensus Rating
Strong Buy

Company Overview

Aptose Biosciences Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
23rd Percentile Overall Score

APTO MarketRank™: 

Aptose Biosciences scored higher than 23% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Aptose Biosciences has received a consensus rating of Strong Buy. The company's average rating score is 3.50, and is based on 1 buy rating, no hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    Aptose Biosciences has received no research coverage in the past 90 days.

  • Read more about Aptose Biosciences' stock forecast and price target.
  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Aptose Biosciences is -0.58, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Aptose Biosciences is -0.58, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Short Interest

    There is no current short interest data available for APTO.
  • Dividend Yield

    Aptose Biosciences does not currently pay a dividend.

  • Dividend Growth

    Aptose Biosciences does not have a long track record of dividend growth.

  • Short Interest

    There is no current short interest data available for APTO.
  • News Coverage This Week

    MarketBeat has tracked 1 news article for Aptose Biosciences this week, compared to 1 article on an average week.
  • MarketBeat Follows

    1 people have added Aptose Biosciences to their MarketBeat watchlist in the last 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Aptose Biosciences insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    Only 1.33% of the stock of Aptose Biosciences is held by insiders.

  • Percentage Held by Institutions

    Only 26.62% of the stock of Aptose Biosciences is held by institutions.

  • Read more about Aptose Biosciences' insider trading history.
Receive APTO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Aptose Biosciences and its competitors with MarketBeat's FREE daily newsletter.

APTO Stock News Headlines

$100 Trillion “AI Metal” Found in American Ghost Town
Jeff Brown recently traveled to a ghost town in the middle of an American desert… To investigate what could be the biggest technology story of this decade. In short, he believes what he's holding in his hand is the key to the $100 trillion AI boom… And only one company here in the U.S. can mine this obscure metal.
Aptose Upgraded to Trade on OTCQB Market
Aptose Provides Corporate Updates
See More Headlines

APTO Stock Analysis - Frequently Asked Questions

Aptose Biosciences Inc. (NASDAQ:APTO) posted its quarterly earnings data on Thursday, August, 8th. The biotechnology company reported ($12.90) earnings per share for the quarter, topping the consensus estimate of ($17.40) by $4.50.

Shares of Aptose Biosciences reverse split before market open on Wednesday, February 26th 2025.The 1-30 reverse split was announced on Tuesday, February 18th 2025. The number of shares owned by shareholders was adjusted after the market closes on Tuesday, February 25th 2025. An investor that had 100 shares of stock prior to the reverse split would have 3 shares after the split.

Based on aggregate information from My MarketBeat watchlists, some other companies that Aptose Biosciences investors own include Digital Turbine (APPS), Okta (OKTA), Canoo (GOEV), CrowdStrike (CRWD) and NVIDIA (NVDA).

Company Calendar

Last Earnings
8/08/2024
Today
7/16/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Biological products, except diagnostic
Sub-Industry
N/A
Current Symbol
NASDAQ:APTO
CIK
882361
Employees
31
Year Founded
N/A

Price Target and Rating

High Price Target
$6.00
Low Price Target
$6.00
Consensus Rating
Strong Buy
Rating Score (0-4)
3.50
Research Coverage
2 Analysts

Profitability

EPS (Trailing Twelve Months)
($89.19)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$51.21 million
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
-5,683.22%
Return on Assets
-300.44%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
1.05
Quick Ratio
1.05

Sales & Book Value

Annual Sales
N/A
Price / Sales
N/A
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
($0.19) per share
Price / Book
N/A

Miscellaneous

Outstanding Shares
2,141,000
Free Float
63,446,000
Market Cap
$3.66 million
Optionable
No Data
Beta
1.04

Social Links

Metaverse Stocks And Why You Can't Ignore Them Cover

Thinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.

Get This Free Report

This page (NASDAQ:APTO) was last updated on 7/16/2025 by MarketBeat.com Staff
From Our Partners